A meta-analysis pooled 4 randomized controlled trials (RCT) of patients with newly diagnosed GBM suggested that adjuvant TMZ beyond 6 cycles did not improve OS, even for patients with MGMT promoter methylation (Blumenthal et al., 2017). The gene discussed is MGMT; the disease is glioblastoma.